Latest filingAug 18, 2026Most recent Form 4
TNYA
Tenaya Therapeutics, Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/10 to 09/10. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$2.10M8 sells
Net open-market-$2.10M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period8transactions
- S · Open-market sells · dominant8 · 100%
Activity by reported role
A joint filing can contribute to multiple roles8transactions
- Chief executive officer · dominant4 · 50%
- CMO4 · 50%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeTingley WhittemoreCommon Stock · Direct
216,352Aug 17, 2026
Ali FarazCommon Stock · Direct
425,188Aug 17, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 10 → Sep 10
LessMore
Top insiders
By absolute net value across the selected period- AF-$15.8k
- TW-$5.3k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
TNYA transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| TNYA | Ali Faraz | CEO | sale | 7.40k | -$525k | S | −1.4% | 08/18 | 08/17 | |
| TNYA | Ali Faraz | CEO | sale | 5.01k | -$356k | S | −1.4% | 08/18 | 08/17 | |
| TNYA | Ali Faraz | CEO | sale | 3.96k | -$281k | S | −1.4% | 08/18 | 08/17 | |
| TNYA | Ali Faraz | CEO | sale | 5.83k | -$414k | S | −1.4% | 08/18 | 08/17 | |
| TNYA | Tingley Whittemore | CMO | sale | 2.27k | -$161k | S | −1.4% | 08/18 | 08/17 | |
| TNYA | Tingley Whittemore | CMO | sale | 1.87k | -$132k | S | −1.4% | 08/18 | 08/17 | |
| TNYA | Tingley Whittemore | CMO | sale | 1.63k | -$116k | S | −1.4% | 08/18 | 08/17 | |
| TNYA | Tingley Whittemore | CMO | sale | 1.63k | -$116k | S | −1.4% | 08/18 | 08/17 |
Tenaya Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Tenaya Therapeutics, Inc.?
Ali Faraz, Tingley Whittemore.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Ali Faraz reported a sale on Aug 17, 2026 valued at $525k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $21,048.00. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.